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Abstract
Follicular lymphoma and diffuse large B cell lymphomas comprise the main entities of adult
B cell malignancies. Although multiple disease driving gene aberrations have been identi-
fied by gene expression and genomic studies, only a few studies focused at the protein
level. We applied 2 dimensional gel electrophoresis to compare seven GC B cell non Hodg-
kin lymphoma (NHL) cell lines with a lymphoblastoid cell line (LCL). An average of 130
spots were at least two folds different in intensity between NHL cell lines and the LCL. We
selected approximately 38 protein spots per NHL cell line and linked them to 145 unique
spots based on the location in the gel. 34 spots that were found altered in at least three NHL
cell lines when compared to LCL, were submitted for LC-MS/MS. This resulted in 28 unique
proteins, a substantial proportion of these proteins were involved in cell motility and cell
metabolism. Loss of expression of B2M, and gain of expression of PRDX1 and PPIA was
confirmed in the cell lines and primary lymphoma tissue. Moreover, inhibition of PPIA with
cyclosporine A blocked cell growth of the cell lines, the effect size was associated with the
PPIA expression levels. In conclusion, we identified multiple differentially expressed pro-
teins by 2-D proteomics, and showed that some of these proteins might play a role in the
pathogenesis of NHL.
Introduction
Follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL) compose 60% of non-
Hodgkin lymphomas (NHLs), both are derived of germinal center or post germinal center B
cells[1]. FL is usually an indolent lymphoma, while DLBCL is an aggressive lymphoma[2,3].
Transformation from FL to DLBCL occurs in 25–30% of the patients[4]. Gene expression
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profiling of DLBCL showed a distinct clustering of cases into two main groups, i.e. germinal
center B cell like (GCB) and activated B cell like (ABC) DLBCL[5,6].
To study the transforming mechanisms for germinal B cell derived lymphomas at the pro-
tein level several proteomics based studies have been conducted. The follicular lymphoma
derived cell line SUDHL-4 was used to identify secreted proteins[7]. In this study 209 proteins
were found with a number of potential candidates for screening, diagnosis and monitoring of
treatment efficiency[7]. Mixtures of cell lines were used to perform quantitative analyses by
2-D gel electrophoresis and SILAC approaches[8–10]. Fujii et al[8,9] compared 42 cell lines
including Hodgkin lymphoma, B, T and NK cell lymphomas to a reference sample which was a
mixture of all cell lines by quantative proteomics. The resulting expression profiles of 389 pro-
teins were used to compare between the different groups of cell lines. Super SILAC was used to
compare cell lysates of 5 GCB and 5 ABC DLBCL cell lines using a heavy stable isotype labelled
mixture of cell lines as a reference. This yielded a proteome consisting of 7,500 proteins and a
subset of 55 proteins that could differentiate between GCB and ABC DLBCL[10]. Comparison
of normal B cells, LPS activated B cells and transgenic Eμ-driven murine B cell lymphoma by
2-D gel electrophoresis revealed 48 differentially expressed proteins[11].
In this study we compared the 2-D proteome profiles of NHL cell lines to Epstein Barr virus
(EBV) transformed lymphoblastoid cell lines (LCL) to identify differentially expressed pro-
teins. Expression of a selection of the differentially expressed proteins (B2M, PRDX1 and
PPIA) was validated in the cell lines and in primary patient material. Inhibition of PPIA with
cyclosporine A (CsA) showed a clear effect on cell growth in all NHL cell lines with a correla-
tion between PPIA expression and sensitivity to CsA induced cell death.
Materials and Methods
Cell lines
DOHH2, SUDHL4 (FL), SUDHL6, SUDHL10, OCILY3, Karpas 422 and SUDHL5 (DLBCL)
were obtained from DSMZ (Braunschweig, Germany). DOHH2, SUDHL4, OCILY3, Karpas
422 cells were routinely grown at 37°C at 5% CO2 in RPMI 1640 supplemented with 10% fetal
calf serum (FCS), ultra-glutamine, penicillin and streptomycin (100U/ml). SUDHL5, SUDHL6
and SUDHL10 cells were cultured with 20% FCS. Five LCLs were generated from peripheral
blood mononuclear cells by infection with B95.8 virus. One LCL was used to compare in the
2-D experiments, the other four were used in the validation and functional studies. LCLs were
routinely grown in RPMI 1640 with 10% FCS. For the production of LCLs from peripheral
blood permission was granted by the Institutional Review board (medical ethical committee
UMCG) and written informed consent was obtained.
Patient material
Tissue samples of 46 patients were collected from the pathology biobank for validation by
immunohistochemistry. These 46 cases, consisted of 13 low grade FL, 8 FL transformed to
DLBCL with evidence of FL in the sample or earlier diagnosis of FL (TFL), and 25 nodal
DLBCL. The 25 DLBCL cases were stained for CD10, BCL6 and MUM1 and classified accord-
ing to the Hans algorithm[12] in GCB (n = 14) and ABC (non-GCB, n = 11). A second group
of 137 DLBCL NOS patients, of which 12 patients were also included in the first cohort, was
used for the validation of B2M expression. The study protocol was consistent with interna-
tional ethical and professional guidelines (the Declaration of Helsinki and the International
Conference on Harmonization Guidelines for Good Clinical Practice). The use of anonymous
rest material is regulated under the code for good clinical practice in the Netherlands. Informed
consent was waived in accordance with Dutch regulations.
Proteomics and B Cell Lymphoma
PLOSONE | DOI:10.1371/journal.pone.0146624 January 11, 2016 2 / 15
Protein extraction
Cells (5–10 x 108) were homogenized in 1 ml of the Homogenize Buffer Mix (BioVision, Milpi-
tas, CA USA) in an ice-cold Dounce homogenizer. The homogenate was centrifuged at 700g
for 10 minutes at 4°C. The supernatants were transferred to a new tube and centrifuged at
10,000g for 30 minutes at 4°C. The total cellular membrane protein pellet was lyzed in lysis
buffer (8M urea, 4% CHAPS, 2% Pharmalyte) and kept on ice for 30 minutes. The supernatants
were harvested by centrifuging at 16,000g for 5 minutes at 4°C. The protein concentrations of
the lysates were determined by Bradford assay.
Two-dimensional polyacrylamide gel electrophoresis fractionation of cell
extracts
100 μg protein was admixed with rehydration buffer (8M urea, 2% CHAPS, 0.28% dithiothrei-
tol and 0.5% Pharmalyte pH 3–10). Immobilized pH gradient strips (11 cm, pH 3–10) were
rehydrated for 12–16 hours after the protein was loaded. Isoelectric focusing (Bio-Rad, Shang-
hai, China) was performed at 20°C by the following program: a linear increase from 0–500V
over 30 minutes, 500–1000V over 1 hour, 1000–5000V over 4 hours, 5000–8000V 4 hour and
then held at 8000V for a total of 64,000Vh. This was followed by a two-step equilibration; first,
strips were put into 10 ml equilibration buffer (6M urea, 30% glycerol, 2% SDS, and 50mM
Tris-HCl, pH 8.8), which contained 1% dithiothreitol for 15 minutes; next, strips were put into
10 ml equilibration buffer with 2.5% iodoacetamide for 25 minutes, and transferred to 12%
SDS polyacrylamide gels. All proteins were visualized by silver staining of the gel, according to
standard protocols.
In each experiment, two gels were run in parallel, one with the LCL sample and the second
gel with one of the lymphoma cell lines. In order to assure reproducibility, all samples were run
at least twice.
All gels were scanned with a GS-710 calibrated imaging densitometer imager. The compara-
tive analysis of gels was performed with PD Quest software (BioRad). The density of each spot
was evaluated by normalizing volumes of all spots. Spots which were consistently up or down-
regulated ( 2-fold) or spots that appeared or disappeared and were showing consistent differ-
ences between LCL and NHL were carefully cut out. For LC-MS/MS spots with the highest
density were selected, destained and digested overnight with 5ng/μl trypsin (freshly made in
20mM ammonium bicarbonate pH 8–8.5). After incubation, formic acid was added and gels
were incubated 5 minutes on a shaker. They were centrifuged at 5,000rpm for 1 minute and the
supernatant was collected for LC-MS/MS analysis with the LTQ-Orbitrap XL (Thermo Scien-
tific, Bremen, Germany).
Protein identification
The peaks and sequences of peptides from selected protein spots were identified by ProteinPi-
lot 3.0 (Applied Biosystems). Proteins were identified by using the UniprotKB/Swiss-Prot data-
base[13]. Proteins with the correct molecular weight and the highest peptide coverage were
considered as the correct protein.
Flow cytometry
Cells were collected by centrifuging at 1200rpm for 5 minutes at 4°C and incubated with an
anti-B2M antibody (1:750, Dako, Glostrup, Denmark) for 30 minutes on ice. Cells were washed
with 1ml 1% PBS/BSA and FITC labeled goat anti rabbit antibody (1:10, Southern Biotech, Bir-
mingham, AL USA) was added as the secondary antibody. Acquisition was performed on a
Proteomics and B Cell Lymphoma
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Calibur flow cytometer (BD Biosciences, San Jose, CA USA) and data were analyzed with Win-
list software.
Quantitative RT-PCR
Total RNA was isolated using QIAzol (Carlsbad, CA USA) and samples were DNAse treated
(Ambion, Foster City, CA USA) according to the manufacturer’s protocol for cell lines. RNA
concentration was quantified using the Nanodrop™ 1000 Spectrophotometer (Thermo Fisher
Scientific Inc., Waltham, MA USA) and RNA integrity was evaluated by 1% agarose electro-
phoresis. cDNA was synthesized using 500ng input RNA, Superscript II and random primer
according to the manufacturer’s protocol (Invitrogen, Bleiswijk, the Netherlands). Primers
used were for PRDX1 forward 5’-AGCCTGTCTGACTACAAAGGAAAATAT-3’ and reverse
5’- GGCACACAAAGGTGAAGTCAAG-3’ and for PPIA forward 5’- AGCTGTTTGCAGA
CAAGGTCC-3’ and reverse 5’-GCAGGAACCCTTATAACCAAATCC-3’. The qPCR reaction
was performed in triplicate in a final volume of 10μl consisting of 5μl SYBR Green mix
(Applied Biosystems, Foster City, CA USA), 2μl of forward and reverse primer (300mM) and
2,5μl 1ng of cDNA. Amplification was performed on a Roche LightCycler1 480 Instrument
(Roche, Almere, the Netherlands). TBP was used as a housekeeping gene and 2-ΔCp values were
calculated.
Immunohistochemistry
Immunohistochemistry was performed according to standard protocols with appropriate posi-
tive and negative controls. Antibodies used were: anti-B2M (1:200, antigen retrieval with TRIS/
EDTA pH9, Dako), anti-PRDX1 (1:200, antigen retrieval with citrate buffer pH6, Abcam,
Cambridge, UK) and anti-PPIA (1:800, antigen retrieval with citrate buffer pH6, Abcam).
Cytotoxicity assay
Cell lines were cultured in triplicate at 105 cells/ml with different concentrations (0–10μg/ml)
of Cyclosporine A and Alamar Blue (Abd Serotec, Oxford, UK). Cultures were measured every
24 hours for 3 days at an emission of 560nm and extinction of 590nm. Experiments were per-
formed 3 times.
Statistical analysis
Statistical analysis was performed with IBM SPSS Statistics 22. The Mann-Whitney U-test was
used to compare B2M, PRDX1, and PPIA expression levels in NHL groups and LCLs for MFI
and mRNA levels. Differences of B2M, PRDX1, and PPIA staining were defined by Chi-square
test for immunohistochemistry. A paired T-test was performed to define the difference in cell
viability before and after cyclosporine A treatment. The correlation of PPIA expression level
and cell viability was defined by Spearman-test. All analyses were two-tailed. P<0.05 was con-
sidered as significant.
Results
Proteome profiles of LCL and NHL cell lines and protein identification
An average of 1,133 (±355) and 1,119 (±330) spots were detected in the 2-D gels of the LCL
and NHL cell lines, respectively (Figure A in S1 File). The paired match rate of spots on control
gels to lymphoma cell line gels ranged from 92 to 96% indicating a good consistency. We
excluded spots that were too weak in both gels or that were incorrectly annotated. This resulted
in an average of 248 (±24) reliable spots per gel that could be used for differential expression
Proteomics and B Cell Lymphoma
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analysis. An average of 130 (±25) spots were at least 2-fold up or downregulated between the
paired NHL and LCL cell lines. We picked 38 (±4) protein spots in each pair of gels, based on
sufficiently high expression levels to analyse and reliable separation on the 2-D gel. Based on
the position in the 2-D gels we were able to link them to 145 unique protein spots. Of these 34
spots were found in at least three NHL cell lines. Spots that were consistently up or downregu-
lated (n = 22) were pooled for protein identification, whereas spots that were up in some and
downregulated in other NHL cell lines (n = 12 spots, resulting in 2x 12 protein IDs) were ana-
lyzed separately. For the 34 spots differentially expressed in 3 or more cell lines a total of 46
analyses were performed. The results are summarized in Table 1. Of the 12 spots that were ana-
lyzed in duplicate and were upregulated in some and downregulated in other cell lines, 7 repre-
sented the same protein, while 5 represented different proteins with similar molecular weights.
Of those 5 spots (10 different proteins) only 4 were found in at least 3 cell lines, the other 6
were removed from further analysis. Four proteins were found twice (PFN1, CFL1, PRDX1
and PPIA) at similar weight but at different iso-electric focusing points, probably due to post-
translational modifications such as phosphorylation, and are indicated as modified.
Fourteen proteins, i.e. B2M, FAHD1, PRDX4, LYZ, CALM1, ARPC5, CALR, TUBB,
PRDX3, RPSA, ATIC, RPS12, PFN1, and CFL1, were downregulated in NHL cell lines com-
pared to LCL cell lines and 8 proteins, i.e. CFL1 (modified), PPIA (modified), MDH2, PRDX1
(modified), MDH1, ENO1, PRDX2 and PCBP1 were upregulated (Fig 1). The remaining 10
proteins, i.e. LGALS1, PFN1 (modified), MYL6, SSBP1, CAPZA1, GSTP1, IDH3A, PPIA,
PRDX1 and PKM, were downregulated in some of the NHL cell lines and upregulated in oth-
ers. The identified proteins are involved in cell motility (n = 6), cell metabolism (n = 5), chro-
matin modification and transcription (n = 5), anti-oxidant (n = 4), immune response (n = 4),
signal transduction and membrane transport (n = 3) and drug metabolism (n = 1)(Fig 1).
We selected B2M, PRDX1 and PPIA for further validation based on the differential expres-
sion patterns in the NHL cell lines and availability of suitable antibodies for immunohis-
tochemistry. B2M plays a role in the immune response, PRDX1 has an anti-oxidant function,
and PPIA is involved in signal transduction.
Validation of B2M
Expression of B2M was absent or reduced in all NHL cell lines compared to the LCL cell line in
the 2-D analysis (Fig 2A). These 2-D results were validated on the cell lines by flow cytometry
(Fig 2D). Four of the NHL cell lines showed lower mean fluorescent intensity (MFI) as com-
pared to the 4 LCLs, consistent with the 2-D analysis, whereas the other three cell lines showed
a similar MFI. Immunohistochemistry of 46 primary cases revealed total loss of B2M expres-
sion in 21% of cases, i.e. 1 out of 13 FL, 2 out of 8 TFL, 5 out of 14 GCB, and 2 out of 11 ABC.
In addition, 9% of the patients showed cytoplasmic staining for B2M, i.e. 1 TFL, 1 GCB, 3 ABC
(Fig 3A–3C), so in total 30% of cases showed no membrane expression of B2M. Since B2M loss
was most common in DLBCL patients, we further checked loss of B2M expression in a larger
cohort of 137 DLBCL patients. Of the 126 evaluable cases 35 (28%) were completely negative
for B2M while 29 patients (23%) showed cytoplasmic expression of B2M, so a loss of mem-
brane B2M expression was observed in a total of 51% of the DLBCL cases.
Validation of PRDX1
PRDX1 (modified) was upregulated in 3 NHL cell lines (SUDHL4, SUDHL6 and SUDHL10)
compared to the LCL cell line. Expression of PRDX1 was upregulated in 2 NHL cell lines
(SUDHL4 and SUDHL10) and downregulated in 1 NHL cell line (SUDHL5)(Fig 2B). PRDX1
mRNA expression levels were higher in SUDHL4, SUDHL10 and SUDHL6 (Fig 2E) compared
Proteomics and B Cell Lymphoma
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Table 1. Altered expression of proteins identified by LC-MS/MS.
spot number protein name UniProtKB/Swiss-Prot Mass (kDa) Sequence coverage (%) Excluded from heatmap
1 RPSA P08865 32.854 64
2 TUBB P07437 49.671 45
3 PRDX1* Q06830 22.11 76
4 PRDX3 P30048 27.693 59
5 CALR P27797 48.142 67
6 PRDX2 P32119 21.892 79
7 MDH1 P40925 36.426 57
8 ARPC5 O15511 16.32 77
9 PFN1 P07737 15.054 74
10 CALM1 P62158 16.838 48
11 LYZ P61626 16.537 18
12 RPS12 P25398 14.515 76
13 ATIC P31939 64.616 66
14 PCBP1 Q15365 37.498 67
15 ENO1 P06733 47.169 47
16A PRDX4 Q13162 30.54 10
16B TPI1 P60174 30.791 60
17A EEF1B2 P24534 24.764 70 ×
17B NUDT5 Q9UKK9 24.328 19 ×
18 CFL1 P23528 18.502 73
19A LGALS1 P09382 14.716 81
19B LGALS1 P09382 14.716 73
20 PPIA* P62937 18.012 75
21A PFN1* P07737 15.054 69
21B PFN1* P07737 15.054 84
22A ECHS1 P30084 31.387 72 ×
22B ACO2 Q99798 85.425 54 ×
23A GNB2L1 P63244 35.077 18 ×
23B MDH2 P40926 35.503 51
24A FAHD1 Q6P587 24.843 37
24B HSD17B10 Q99714 26.923 26 ×
25 CFL1* P23528 18.502 83
26A PKM P14618 57.937 69
26B PKM P14618 57.937 4
27 B2M P61769 13.715 71
28A MYL6 P60660 16.961 63
28B MYL6 P60660 16.961 26
29 SSBP1 Q04837 17.260 27
30A CAPZA1 P572907 32.923 57
30B CAPZA1 P572907 32.923 26
31A GSTP1 P09211 23.356 32
31B GSTP1 P09211 23.356 68
32A IDH3A P50213 39.592 27
32B IDH3A P50213 39.592 29
33 PRDX1 Q06830 22.110 53
34 PPIA P62937 18.012 82
*: modiﬁed protein
doi:10.1371/journal.pone.0146624.t001
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to the LCL cell lines, consistent with the 2-D results. In contrast, SUDHL5 had the highest
mRNA levels, while in the 2-D experiment PRDX1 protein levels were downregulated com-
pared to the LCL cell line.
Immunohistochemistry of the 46 primary NHL cases showed positive staining in 33 cases
(72%). In FL, 5 of the 13 cases were positive with 4 cases showing weak positive and 1 case
Fig 1. Heatmap of 2-D spots with different intensities in NHL compared with the LCL cell line. Proteins that were differentially expressed in at least 3
cell lines are shown. In total, 28 different proteins have been found and 4 proteins were also found in a modified form (*). Blue: protein spot is missing in NHL
cell lines. Light blue: protein spot is down-regulated in NHL cell lines. Red: protein spot is missing in LCLs and thus increased in NHL cell lines. Light red:
Protein spot is weaker in LCL and thus elevated in NHL cell lines. Gene ontology was checked to classify the proteins according to function.
doi:10.1371/journal.pone.0146624.g001
Proteomics and B Cell Lymphoma
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Fig 2. Expression of B2M, PRDX1 and PPIA. (A-C) Silver stained 2 Dimensional SDS PAGE gels. Differential expressed spots have been circled.
Continuous circles indicate differential expression was more than 2 fold. Dotted circles indicate difference in expression level was less than 2 fold. Upper line
pictures are LCL and lower lines are NHL cell lines. (A) SUDHL10, Karpas 422, SUDHL4, OCILY3, DOHH2, SUDHL6 and SUDHL5 are shown. Loss of B2M
is observed in SUDHL10 and Karpas 422, decreased expression of B2M is seen in SUDHL4, OCILY3 and DOHH2, and moderate decreased expression of
B2M is seen in SUDHL6 and SUDHL5 compared to LCL. (B) SUDHL4, SUDHL6, SUDHL10 and SUDHL5 are shown. Modified proteins are located on the
left. Elevated expression of PRDX1 is observed in SUDHL4, SUDHL10 and decreased expression of PRDX1 in SUDHL5 compared to LCL. Elevated
expression of modified PRDX1 is observed in SUDHL4, SUDHL10 and SUDHL5 compared to LCL. (C) SUDHL4, DOHH2, Karpas 422 and OCILY3 are
shown. Modified proteins are located on the left. Elevated expression of PPIA is observed in SUDHL4, DOHH2 and decreased expression of PPIA in OCILY3
compared to LCL. Elevated expression of modified PPIA is observed in SUDHL4, DOHH2, OCILY3 and Karpas 422 compared to LCL. (D) The mean
fluorescent intensity of B2M expression determined by flow cytometry. (E) The mRNA expression level of PRDX1. (F) The mRNA expression level of PPIA.
Mann-Whitney U test was used to compare the differences in B2M, PRDX1, and PPIA expression between the NHL cell line group and LCL group (**:
p<0.01).
doi:10.1371/journal.pone.0146624.g002
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showing strong positive staining. Of the TFL cases, 3 showed weak positive staining and 3
strong staining. In GCB DLBCL 10 cases were weak positive and 3 cases were strong positive.
Of the ABC DLBCL cases 5 showed weak positive staining and 4 showed strong staining
(Fig 3D–3F). When comparing the staining pattern of PRDX1 in the NHL subtypes, a signifi-
cant difference (p = 0.0409) was found. Comparison of the staining results between the three
lymphoma subtypes revealed a significant difference between FL and GCB-DLBCL
(p = 0.0112).
Validation of PPIA
The expression of PPIA (modified) was upregulated in 4 cell lines (DOHH2, SUDHL4,
OCILY3 and Karpas 422) compared to LCL in the 2-D gels. The unmodified PPIA was upregu-
lated in 2 cell lines (DOHH2 and SUDHL4) and downregulated in 1 cell line (SUDHL6)
(Fig 2C).
PPIA mRNA expression levels were upregulated in all NHL cell lines compared to LCLs
(p = 0.0040, Fig 2F). SUDHL4 mRNA levels were highest, fitting the 2-D pattern, while the
Fig 3. Immunohistochemistry staining of B2M, PRDX1 and PPIA. (A-C) B2M, (D-F) PRDX1, (G-I) PPIA. (A, D, G) negative cases, (B, E, H) positive
cases. (C, F, I) Percentage of positive cases in different types of NHLs. Black bar indicates positive staining; grey bar indicates cytoplasmic staining for B2M
and weak staining for PRDX1 and PPIA; white bar indicates negative staining. Chi-square test were performed to determine the differences in the B2M,
PRDX1, and PPIA staining between the NHL subtypes (*: p<0.05; **: p< 0.01).
doi:10.1371/journal.pone.0146624.g003
Proteomics and B Cell Lymphoma
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other NHL cell lines with upregulated protein levels in the 2-D (DOHH2, OCILY3 and Karpas
422) analysis were amongst the lowest at the mRNA levels. Immunohistochemistry of primary
cases revealed in most of the FL cases (8 of 13) weak positive staining, while all 8 TFL cases
showed strong positive staining for PPIA. GCB and ABC DLBCL staining results were compa-
rable with 9 and 7 strong positive cases, for ABC the remaining cases were weak positive, while
for GCB they were partly weak and partly negative. The results are summarized in Fig 3G–3I.
The pattern of PPIA expression in primary patient material was significantly different
(p = 0.0418) with the significant difference between FL and TFL (p = 0.0079).
To further investigate the role of PPIA in NHL, we inhibited PPIA in all cell lines with
cyclosporine A (CsA). After treating the cells for 72 hours with different concentrations (0, 0.5,
1, 2, 5, 10 μg/ml) of CsA the viability of LCL and NHL cell lines was assessed (Fig 4; Figure B in
S1 File). The NHL cell lines were significantly more sensitive to the effect of CsA than the LCL
cell lines at each concentration. SUDHL5 and SUDHL10 were most sensitive. To explore
whether the expression level of PPIA is related to the sensitivity of CsA treatment, we corre-
lated the PPIA mRNA level with the relative cell viability of 7 NHL and 4 LCL cell lines upon
treatment with CsA. A significant negative correlation was observed between PPIA mRNA
level and the viability of cells after CsA treatment, with the most significant effect in cells
treated with 5 μg/ml CsA (p = 0.0064, r2 = 0.6112; Fig 4; Figure B in S1 File).
Discussion
Our 2-D gel electrophoresis approach revealed 28 differentially expressed proteins in lym-
phoma cell lines compared to LCLs. LCLs were chosen since they are cell lines and have similar
proliferation patterns, while normal B cells are in a resting stage. For LCLs the transformation
mechanism is by EBV and its proteins, and should be different from the NHL cell lines. The
identified proteins are involved in various processes relevant to the pathogenesis of B cell lym-
phoma including cell motility and metabolism.
The proteins included in the cell motility gene ontology are ARPC5, TUBB, CFL1, MYL6,
CAPZA1 and PFN1. With the exception of the modified CFL1 and PFN1, these proteins are all
downregulated in NHL. ARPC5, CFL1, CAPZA1 and PFN1 have been shown to play roles in
metastasis and invasion of solid tumors. Downregulation of ARPC5 blocks metastasis[14],
whereas downregulation of CAPZA1[15] and PFN1[16] enhances metastasis and invasion or
motility of cells. The presence of phosphorylated CFL1[17] is associated with metastasis, and
phosphorylated PFN1[18] leads to enhanced angiogenesis via the upregulation of HIF1α. The
functional consequences of downregulation of this group of proteins in NHL remains
unknown. The proteins associated with metabolism are involved in the process known as the
Warburg effect[19], which is a hallmark of cancer. PKM and ENO-1 are part of glycolysis,
while IDH3, MDH1 and MDH2 are part of the Krebs cycle. Four of the five metabolism pro-
teins are upregulated in NHL, except for IDH3 which was downregulated in 2 cell lines and
upregulated in one. The PRDX proteins (anti oxidative proteins) are indirectly related to the
Warburg effect, since reactive oxygen species levels are up as a result of the Warburg effect and
the PRDX proteins can neutralize that effect. Upregulation of PRDX1 and PRDX2 fits with the
upregulation of metabolism proteins, however, PRDX3 and PRDX4 were downregulated in
NHL compared to LCL cell lines.
Various proteins identified by us as differentially expressed in NHL compared to LCL have
been identified in B cell lymphoma previously. In the Eμ-driven mouse model Romesser et al
found differential expression of ENO1, CALR, CFL1 and PPIA by comparing the proteome of
activated B cells to B cell lymphoma[11] Consistent with their results we found downregulation
of CALR and upregulation of the modified CFL1 protein and PPIA in lymphoma compared to
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LCL cells. The unmodified CFL1 protein was downregulated in our experiments, suggesting a
shift towards the modified form of the CFL1 protein, which could indicate a more active form
due to for example phosphorylation. PRDX1 expression was reported in a LCL cell line[20]
and in DLBCL[21]. We found upregulation of PRDX1 in NHL compared to LCL. PRDX4 was
shown to be upregulated in DLBCL[21], while we found downregulation in NHL compared to
LCL. Protein levels of GSTP1 were reported to be high in 29% of DLBCL cases and low in all
FL cases[22] Expression of GSTP1 has also been found with 2-D electrophoresis in a LCL cell
line[23]. In our study, GSTP1 was downregulated in 2 cell lines and upregulated in one cell
Fig 4. Sensitivity of NHL and LCL cell lines to inhibition of PPIA by 5 μg/ml CsA. (A) The inhibition of cell
viability after CsA treatment. After adding 5 μg/ml CsA for 72 hours, the viability of NHL and LCL cell lines was
evaluated by alamar blue assay. A paired T-test was performed to compare the cell viability before and after
treatment. Mann-Whitney U test was used to compare the cell viability between the NHL cell line group and
LCL group. (*: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001) (B) The correlation between PPIA
expression level and the inhibition of cell viability after NHL cell lines treated with 5 μg/ml CsA for 72 hours.
Statistical significance was determined by Spearman test (p = 0.0064, r2 = 0.6112). There is a negative
correlation between the relative PPIA expression and the % of viability after CsA treatment.
doi:10.1371/journal.pone.0146624.g004
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line. Loss of B2M has been described previously in DLBCL of testis and the central nervous sys-
tem as well as in DLBCL NOS[24,25]. B2M levels were decreased in all seven NHL cell lines
compared to LCL. LGALS1 expression has been reported in 7% of DLBCL[26]. In LCLs and
EBV+ post-transplant lymphoproliferative disorders expression of LGALS1 has been reported
upregulated[27]. We found downregulation in 3 cell lines and upregulation in 1 cell line, com-
parable to the reported data. Thus 9 of 28 proteins identified in this study have been reported
in B cell lymphoma before and showed expression changes consistent with the literature.
B2M, expression is downregulated or absent in all NHL cell lines compared to LCL cells.
This observation is partially supported by flow cytometry and IHC staining. B2M is one of the
polypeptide chains of human leukocyte antigen class I (HLA class I), and both chains are essen-
tial for membrane expression of HLA class I. Loss of HLA class I expression provides an
immune escape mechanism for tumor cells. A number of studies have shown loss of HLA class
I in DLBCL patients, especially in DLBCL presenting at immune privileged sites[28]. Loss of
B2Mmembrane expression has been published in up to 60% of DLBCL cases[25]. In our
DLBCL cohort we found loss of B2Mmembrane expression in 51% of cases. Another differen-
tially expressed protein we identified, CALR, has also been associated with antigen presenta-
tion[29]. CALR expression is decreased or lost in some NHL cell lines compared to LCLs.
CALR is a chaperone molecule for HLA class I stability, as well as a chaperone for misfolded
proteins[29]. Loss of CALR might be part of the immune escape mechanism or alternatively be
a consequence of the loss of HLA class I expression.
PRDX1 expression is elevated at protein and mRNA level in part of NHL cell lines com-
pared to LCL cells. In patient samples, we observed a higher proportion of strong positive and
positive PRDX1 expression in the more aggressive TFL and DLBCL as compared to the indo-
lent FL, this difference is most pronounced in the comparison between GCB-DLBCL and FL.
Peroxiredoxins are thiol peroxidases, that play a role in maintaining the redox balance and
have anti-apoptotic ability. PRDX1 is expressed in germinal center B cells and plasma cells and
in germinal center derived B cell lymphomas and multiple myeloma[21]. The expression of
PRDX1 in NHL could play a role in protection against apoptosis or be part of the Warburg
effect.
PPIA, expression was elevated in the 2-D in 3 cell lines and mRNA levels are consistently
higher in NHL cell lines compared to LCL cells. In addition, PPIA protein expression is higher
in aggressive TFL and DLBCL as compared to the indolent FL. PPIA belongs to the immuno-
philin family, which catalyzes cis-trans isomerization during protein folding. Elevation of PPIA
expression has been observed in some solid cancers, such as non-small cell lung carcinoma[30]
and gastric cancer[31]. Knockdown of PPIA can inhibit growth of non-small cell lung carci-
noma cells[32]. PPIA supports neoplastic cell proliferation, cell cycle progression and invasion,
while protecting them from apoptosis, by activating signaling pathways, such as NF-κB [33],
and ERK1/2 [34]. PPIA can also be secreted into the circulation to attract monocytes and stim-
ulates monocytes to produce IL-6[35,36], and thereby create a pro-tumor microenvironment.
Cyclosporin A (CsA), a widely used immune suppressive drug, binds to PPIA and inhibits its
function. In T cells, CsA inhibits transcription factor NF-AT which is important in activation
of T cells. In our study, there is a correlation between PPIA mRNA level and CsA induced cell
death. The lymphoma cell lines showed significant more inhibition of cell growth than the
LCLs, at all tested CsA levels. CsA suppressed tumor progression of squamous cell carcinoma
and murine B cell lymphoma in a mouse model[37]. In mouse xenograft models for bladder
cancer[38] and breast cancer[39] CsA treatment prevented tumor growth. The use of CsA in
patients has been tested in angioblastic T cell lymphoma, with a response to therapy in 8 out of
12 patients[40]. These data support CsA treatment as a novel therapy in PPIA positive DLBCL.
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However, the induction of EBV+ lymphoproliferative disease is a severe and well known side
effect of long-term immune suppression by CsA in the post-transplantation setting.
In summary, we identified 28 differentially expressed proteins and validated the expression
in primary tissue samples for three selected proteins. The finding of B2M and PRDX1 con-
firmed validity of our approach as it has been shown previously in NHL. Elevated PPIA expres-
sion in lymphoma compared with LCL cells is novel and its oncogenic potential is supported
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